Get the Stockscreener App
1.90
97.92%
0.94
After Hours:
2.06
0.16
+8.42%
Chromocell Therapeutics Corp stock is traded at $1.90, with a volume of 14.11M.
It is up +97.92% in the last 24 hours and up +206.70% over the past month.
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
See More
Previous Close:
$0.96
Open:
$1.09
24h Volume:
14.11M
Relative Volume:
38.78
Market Cap:
$11.45M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+110.51%
1M Performance:
+206.70%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.00
$2.45
1-Week Range:
$0.81
$2.45
52-Week Range:
$0.45
$2.45
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
Name
Chromocell Therapeutics Corp
Sector
Industry
Phone
(917) 644-6313
Address
685 US HIGHWAY ONE, NORTH BRUNSWICK
Compare CHRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
1.90 | 11.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chromocell Therapeutics Corp Stock (CHRO) Latest News
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - Quantisnow
Chromocell Therapeutics Announces Name Change to Channel Therapeutics Corporation and Provides Therapeutic Program Updates - Defense World
Chromocell Announces Name Change to 'Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - The Manila Times
Chromocell changes name to Channel Therapeutics, provides program updates - TipRanks
Channel Therapeutics Corporation Provides Therapeutic Program Update - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Certain Warrants of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announces an Equity Buyback for $0.25 million worth of its shares. - Marketscreener.com
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Certain Common Stock of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Certain Series A Preferred Stock of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announced that it expects to receive $0.75 million in funding - Marketscreener.com
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 - Marketscreener.com
Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program - Marketscreener.com
Chromocell Therapeutics Corporation announced that it has received $0.75 million in funding - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Channel Therapeutics Advances Non-Opioid Pain Programs, Reports 96-Hour Drug Release Success - StockTitan
Channel Therapeutics announces corporate restructuring By Investing.com - Investing.com Australia
Channel Therapeutics announces corporate restructuring - Investing.com India
Channel Therapeutics finalizes corporate restructuring By Investing.com - Investing.com Canada
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times
Chromocell announces amendment to stock repurchase plan - MSN
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell boosts stock buyback plan to $750,000 - Investing.com India
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Chromocell boosts stock buyback plan to $750,000 By Investing.com - Investing.com South Africa
Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Upward Trajectory: Chromocell Therapeutics Corp. (CHRO) Posts a Slidee, Closing at 0.84 - The Dwinnex
CHRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Chubb (CB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Stocks of Chemours Company (CC) are poised to climb above their peers - SETE News
Chubb Limited [CB] stock was sold by GREENBERG EVAN G at the price of US$8.78 million - Knox Daily
Recent 4.1% pullback isn't enough to hurt long-term Calumet (NASDAQ:CLMT) shareholders, they're still up 373% over 5 years - Yahoo Finance
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $18.00 - Defense World
Market Update: Calumet Inc. (CLMT) Sees Negative Movement, Closing at 18.00 - The Dwinnex
C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CG Oncology initiated with an Outperform at RBC Capital - TipRanks
Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World
Chubb Stock Trading Near 52-Week High: What Should Investors Know? - Yahoo Finance
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Morningstar
Choreo LLC Purchases New Stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
CorMedix stock soars to 52-week high, hits $7.29 By Investing.com - Investing.com Australia
Chromocell Therapeutics Corp Stock (CHRO) Financials Data
There is no financial data for Chromocell Therapeutics Corp (CHRO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Cap:
|
Volume (24h):